Singapore, April 15, 2025 – ChemT Biotechnology took part in the Bio Innovation Leaders Summit (BILS) held in Singapore this week. Co-founder Dr. Ling Wu delivered a keynote address on leveraging artificial intelligence to enhance efficiency in biologics manufacturing.

In his presentation, Dr. Wu showcased how generative AI, large language models (LLMs), and computational tools can accelerate biologics development by overcoming challenges such as labor-intensive workflows and scalability limitations.

Dr. Ling Wu, Co-founder of ChemT Bio, on the impact of AI:

“AI is unlocking a new era in biomanufacturing—one where we can overcome long-standing bottlenecks, accelerate production, and bring innovative treatments to more patients around the world.”

The session was part of ongoing discussions at BILS about how AI can help solve long-standing challenges in therapeutic development and manufacturing.